Inflation expectations over the next 10 years have risen to their highest level since 2023. The 10-year inflation breakeven rate — the difference between the 10-year Treasury yield ( US10Y ) ( TBT ) ( TLT ) and the 10-year TIPS yield ( TIP ) — climbed to 2.5% (H/T Bloomberg). The 10-year breakeven last hit 2.5% in March 2023. It also approached that level in October 2023, topping out at 2.49%. The...
Inflation expectations over the next 10 years have risen to their highest level since 2023. The 10-year inflation breakeven rate — the difference between the 10-year Treasury yield ( US10Y ) ( TBT ) ( TLT ) and the 10-year TIPS yield ( TIP ) — climbed to 2.5% (H/T Bloomberg). The 10-year breakeven last hit 2.5% in March 2023. It also approached that level in October 2023, topping out at 2.49%. The most recent low was 2.02% in September 2024. Looking at current price activity, Truflation’s daily CPI is running at a 1.95% annual rate, with gasoline, other fuels and motor oil higher and food lower. That compares with the March headline CPI of 3.3% reported by the BLS. FRED (St. Louis Federal Reserve) More on United States 10-Year Bond Yield Rates Spark: 10yr SOFR Hits The 4% Handle Oil Spikes Rhyme Through Time Bond Market On Edge: Treasury Yields Spike, 30-Year To 5.03%, Mortgage Rates To 6.52%, As Gulf War Reheats Yields climb as oil surges, Middle East risks shake rate cut bets April jobs report poised to undercut recovery narrative - Pantheon Macro
jetcityimage/iStock Editorial via Getty Images Investment Thesis Eli Lilly's ( LLY ) core GLP-1 business is in a tight race with Novo Nordisk ( NVO ). Although tirzepatide is much more effective than semaglutide, neither company's pipeline indicates a clear winner, raising questions about Eli Lilly's premium valuation. Eli Lilly's oncology business shows a similar close competition, as Novartis's ...
jetcityimage/iStock Editorial via Getty Images Investment Thesis Eli Lilly's ( LLY ) core GLP-1 business is in a tight race with Novo Nordisk ( NVO ). Although tirzepatide is much more effective than semaglutide, neither company's pipeline indicates a clear winner, raising questions about Eli Lilly's premium valuation. Eli Lilly's oncology business shows a similar close competition, as Novartis's ( NVS ) Kisqali and Fulvestrant provide a higher median PFS at the expense of less convenience due to injections. I therefore rate Eli Lilly as 'Hold.' This rating is due to a long-term outlook that is far less promising than the current state of the business, along with a high market valuation, which does not offer a high return opportunity. Business Overview Eli Lilly, based in Indianapolis, is the world's biggest pharmaceutical company. Its products can be divided into four segments. Based on the percentage of total revenue, the biggest and most important segment lies in cardiometabolic health, accounting for almost 80% of revenue . Key products are Mounjaro and Zepbound, accounting for 55% and 26% of cardiovascular revenue, respectively. Both products contain the active ingredient tirzepatide, a dual-agonist consisting of GLP-1 and GIP. Tirzepatide is manufactured by both Eli Lilly themselves and external manufacturers called CDMOs. Four facilities located in the US, Germany, and Ireland currently supply tirzepatide , while the remaining peptides are composed across more than 50 CDMOs . To grow along with the demand, Eli Lilly is forced to keep investing in expanding those facilities, as they have been doing in the past. After manufacturing, Eli Lilly fills its pens with the active ingredient. This process is done in Italy, Germany, and the US by themselves or, again, outsourced to external partners. The therefore needed materials, like needles and glass cartridges, are supplied by external partners like Ypsomed ( YPHDF ) and Gerresheimer ( GRRMF ). In the past , this c...
Bullish agreed to buy Equiniti from Siris Capital in a $4.2 billion deal, as the crypto exchange seeks to expand in blockchain-based capital markets infrastructure. Bullish will pay about $2.35 billion in stock and assume $1.85 billion of Equiniti debt as part of the transaction, according to a filing on Tuesday. The deal, which includes an option for Siris to buy non-core Equiniti business lines,...
Bullish agreed to buy Equiniti from Siris Capital in a $4.2 billion deal, as the crypto exchange seeks to expand in blockchain-based capital markets infrastructure. Bullish will pay about $2.35 billion in stock and assume $1.85 billion of Equiniti debt as part of the transaction, according to a filing on Tuesday. The deal, which includes an option for Siris to buy non-core Equiniti business lines, is expected to close in January 2027, Bullish said. Major crypto exchanges have resorted to acquisitions in past months to expand their offerings and lessen their dependence on volatile trading in digital tokens. In April, the parent of the Kraken exchange said it’s buying derivatives platform Bitnomial Inc. for up to $550 million. Read more: Crypto Exchange Kraken to Buy Bitnomial for Up to $550 Million “Broad adoption at institutional scale requires three things: end-to-end tokenization services, a single, unified ledger, and a broad base of blue-chip issuer relationships, at scale,” Bullish Chief Executive Officer Tom Farley said in the statement. “This combination delivers all three.”
Jonathan Kitchen Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny and micro-cap stocks often struggle to meet the profitability, growth, and momentum thresholds that drive high quant scores. All 10 names on this list carry Strong Buy ratings above 4.94, placing them among the ...
Jonathan Kitchen Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny and micro-cap stocks often struggle to meet the profitability, growth, and momentum thresholds that drive high quant scores. All 10 names on this list carry Strong Buy ratings above 4.94, placing them among the highest-rated stocks in the entire Seeking Alpha universe regardless of price, a signal that the quantitative case for these names is unusually compelling relative to their peers. Topping the list is Alto Ingredients ( ALTO ), which holds a near-perfect Quant Rating of 4.99, consistent with a Zacks upgrade to Strong Buy in March 2026 and analyst price targets as high as $5.50, suggesting meaningful upside from current levels. Commercial Vehicle Group ( CVGI ), Ironwood Pharmaceuticals ( IRWD ), Netlist ( NLST ), and Gran Tierra Energy ( GTE ) follow with ratings of 4.98 each, representing a diverse cross-section of industrials, pharmaceuticals, technology, and energy that underscores how broadly the quant system has identified value in the under-$10 space. Here is the list: Alto Ingredients, Inc. ( ALTO ), Quant Rating: 4.99 Commercial Vehicle Group, Inc. ( CVGI ), Quant Rating: 4.98 Ironwood Pharmaceuticals, Inc. ( IRWD ), Quant Rating: 4.98 Netlist, Inc. ( NLST ), Quant Rating: 4.98 Gran Tierra Energy Inc. ( GTE ), Quant Rating: 4.98 Tilly’s, Inc. ( TLYS ), Quant Rating: 4.97 Imperial Petroleum Inc. ( IMPP ), Quant Rating: 4.96 Kosmos Energy Ltd. ( KOS ), Quant Rating: 4.95 Vince Holding Corp. ( VNCE ), Quant Rating: 4.94 POET Technologies Inc. ( POET ), Quant Rating: 4.94 More on Gran Tierra, Alto Ingredients, etc. POET Technologies: Why I'm Still Bullish Despite The Marvell Drama And Legal Risks POET Technologies: High Double-Digit Annualized Return, Lower Price Target, Rating Downgrade POET: I Called The Surge, Now Reset Kosmos Energy GAAP EPS of -$0.45 misses by $0.47...
Advanced Energy ( AEIS ) declares $0.10/share quarterly dividend , in line with previous. Forward yield 0.1% Payable June 5; for shareholders of record May 25; ex-div May 21. See AEIS Dividend Scorecard, Yield Chart, & Dividend Growth. More on Advanced Energy Advanced Energy Industries, Inc. 2026 Q1 - Results - Earnings Call Presentation Advanced Energy Industries, Inc. (AEIS) Q1 2026 Earnings Cal...
Advanced Energy ( AEIS ) declares $0.10/share quarterly dividend , in line with previous. Forward yield 0.1% Payable June 5; for shareholders of record May 25; ex-div May 21. See AEIS Dividend Scorecard, Yield Chart, & Dividend Growth. More on Advanced Energy Advanced Energy Industries, Inc. 2026 Q1 - Results - Earnings Call Presentation Advanced Energy Industries, Inc. (AEIS) Q1 2026 Earnings Call Transcript Advanced Energy Industries, Inc. (AEIS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Advanced Energy forecasts low-to-mid-20% 2026 revenue growth as it targets over 43% gross margin Advanced Energy Non-GAAP EPS of $2.09 beats by $0.11, revenue of $511M beats by $5.22M
Palantir Technologies Inc. (NASDAQ:PLTR) delivered its fastest revenue growth since at least 2020 and lifted its full-year 2026 guidance well above Wall Street expectations, yet its shares declined roughly 3% in premarket trading on Tuesday.
Palantir Technologies Inc. (NASDAQ:PLTR) delivered its fastest revenue growth since at least 2020 and lifted its full-year 2026 guidance well above Wall Street expectations, yet its shares declined roughly 3% in premarket trading on Tuesday.
The improved form of McLaren and Red Bull and in Florida suggests the 2026 title race is likely to run and run There is a long old way to go but after Formula One emerged from its enforced early season break with an entertaining romp around the Hard Rock Stadium in Miami, it indicated that there may yet be a decent tale to be told this season. One where Mercedes do not have it all their own way. R...
The improved form of McLaren and Red Bull and in Florida suggests the 2026 title race is likely to run and run There is a long old way to go but after Formula One emerged from its enforced early season break with an entertaining romp around the Hard Rock Stadium in Miami, it indicated that there may yet be a decent tale to be told this season. One where Mercedes do not have it all their own way. Regulation changes dominated the buildup – of which more later because honestly paragraph two is too early to subject readers to the increasingly soul-destroying phrase “energy management” – but what really mattered in Miami was the sporting imperative of upgrades making a competitive difference. Continue reading...
(RTTNews) - Leidos Holdings, Inc. (LDOS), a provider of technology and engineering services, on Tuesday reported that its first quarter net income declined, but adjusted net income increased compared with the previous year.
(RTTNews) - Leidos Holdings, Inc. (LDOS), a provider of technology and engineering services, on Tuesday reported that its first quarter net income declined, but adjusted net income increased compared with the previous year.
Five9 ( FIVN ) has entered into an accelerated share repurchase, or ASR, agreement with JPMorgan Chase Bank, National Association ( JPM ) to buy back $90M of its stock under its existing authorization. The company will pay $90M upfront on May 5, 2026, and expects to receive about 3.1M shares initially. The final number of shares will depend on the stock’s average price over the duration of the pro...
Five9 ( FIVN ) has entered into an accelerated share repurchase, or ASR, agreement with JPMorgan Chase Bank, National Association ( JPM ) to buy back $90M of its stock under its existing authorization. The company will pay $90M upfront on May 5, 2026, and expects to receive about 3.1M shares initially. The final number of shares will depend on the stock’s average price over the duration of the program, adjusted for a discount. The ASR is expected to be completed by September 30, 2026. More on Five9 Five9: I'm Buying The AI Growth Reacceleration Five9, Inc. 2026 Q1 - Results - Earnings Call Presentation Five9, Inc. (FIVN) Q1 2026 Earnings Call Transcript Five9 signals $1.266B 2026 revenue outlook while planning to complete $150M buyback by end of Q3 Five9 Non-GAAP EPS of $0.76 beats by $0.08, revenue of $305.32M beats by $5.25M
The rebound in global stocks from their Iran war lows has been so narrow that the market is primed for broader gains triggered by even slightly positive news, according to strategists at JPMorgan Chase & Co. Volatility is likely in the near term, but investors with a time horizon longer than the next days or weeks should keep using dips in equities to add exposure, the team led by Mislav Matejka s...
The rebound in global stocks from their Iran war lows has been so narrow that the market is primed for broader gains triggered by even slightly positive news, according to strategists at JPMorgan Chase & Co. Volatility is likely in the near term, but investors with a time horizon longer than the next days or weeks should keep using dips in equities to add exposure, the team led by Mislav Matejka said. While the V-shaped rally in MSCI Inc.’s Word Index may look like a disconnect from soaring oil prices, the gains have been driven by a very small group of stocks, they said. Investor positioning is lighter than before the war started, supporting the case for gains to spread as factors holding back buying ease. “Equities are not all that complacent beneath the surface,” Matejka said in a client note. Nearly all consumer plays, for instance, are languishing near their lows, he said. Strong earnings will continue to support equities and while valuations look stretched in the US, international stocks appear cheaper. Read more: Concentration Shaping Up as Key Risk for Investors: Taking Stock Concentration risk has emerged as a major concern for investors this year. Since the start of 2026, seven stocks have generated about 84% of S&P 500 Index returns, while in Europe, six companies account for over 90% of Stoxx Europe 600 gains. In the US, the rally is almost entirely driven by megacap technology. While Europe offers more diversification, the absence of Big Tech leaves three energy firms as the primary driver, accounting for 40% of returns. The JPMorgan strategists said that in the near term, gains are likely to remain narrow, with a rebound in mega-cap technology stocks acting as a key driver. However, they expect broader participation to develop later in the year, with leadership rotating toward value stocks, small caps and international markets. An escalation in the Middle East conflict would make an off-ramp more likely, as rising US gasoline prices, adverse polling am...